Sotera Health Company (NASDAQ:SHC) Stock Has Consensus Price Target of $21.38 According to Analysts

Key Points

• Analyst sentiment is moderately bullish: Nine of 11 analysts rate Sotera Health a buy, with an average 12-month price target of $21.38 versus the stock’s reported $17.64 price.
• Recent financial results exceeded expectations: Sotera Health reported quarterly EPS of $0.26 against a $0.24 consensus estimate, while revenue of $321.38 million rose 9.2% year over year and surpassed forecasts.
• Ownership activity was mixed: Insiders sold roughly $24 million of shares over the past 90 days, while hedge funds and other institutions—including BlackRock—added significant positions; institutional investors own 91.03% of the stock.

Sotera Health Company (NASDAQ:SHC - Get Free Report) has received an average recommendation of "Moderate Buy" from the eleven analysts that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and nine have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $21.38.

A number of research analysts recently issued reports on SHC shares. JPMorgan Chase & Co. restated an "underweight" rating and set a $17.00 price target on shares of Sotera Health in a research note on Wednesday, October 14th. Wall Street Zen downgraded shares of Sotera Health from a "strong-buy" rating to a "buy" rating in a research report on Saturday. Barclays increased their price target on shares of Sotera Health from $19.00 to $22.00 and gave the company an "overweight" rating in a report on Friday, August 7th. Citigroup boosted their target price on Sotera Health from $23.00 to $25.00 and gave the stock a "buy" rating in a research report on Friday, August 7th. Finally, Weiss Ratings raised Sotera Health from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Thursday, October 8th.

Insider Activity at Sotera Health

In other Sotera Health news, insider Michael P. Rutz sold 150,000 shares of the business's stock in a transaction on Friday, August 7th. The stock was sold at an average price of $18.84, for a total value of $2,826,000.00. Following the completion of the transaction, the insider directly owned 334,279 shares in the company, valued at approximately $6,297,816.36. The trade was a 30.97% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Chairman Michael B. Jr. Petras sold 850,000 shares of the company's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $18.50, for a total value of $15,725,000.00. Following the completion of the transaction, the chairman owned 3,969,393 shares of the company's stock, valued at $73,433,770.50. The trade was a 17.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 1,294,515 shares of company stock valued at $23,999,528 over the last ninety days. 15.36% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in SHC. BlackRock Inc. acquired a new position in Sotera Health in the second quarter worth about $428,635,000. Sculptor Capital LP bought a new position in shares of Sotera Health during the second quarter worth about $426,000,000. Jupiter Topco LLC acquired a new stake in shares of Sotera Health in the second quarter valued at approximately $149,137,000. Two Seas Capital LP acquired a new stake in Sotera Health in the 2nd quarter valued at approximately $103,590,000. Finally, Lakewood Capital Management LP bought a new stake in shares of Sotera Health during the second quarter valued at about $70,638,000. 91.03% of the stock is owned by hedge funds and other institutional investors.

Sotera Health Stock Performance

Shares of SHC stock opened at $17.64 on Tuesday. The firm has a fifty day moving average price of $18.64 and a 200 day moving average price of $17.22. The company has a market cap of $5.03 billion, a P/E ratio of 30.95 and a beta of 1.85. Sotera Health has a 12 month low of $13.09 and a 12 month high of $19.85. The company has a current ratio of 2.80, a quick ratio of 2.55 and a debt-to-equity ratio of 3.33.

Sotera Health (NASDAQ:SHC - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.26 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.24 by $0.02. The firm had revenue of $321.38 million during the quarter, compared to the consensus estimate of $309.70 million. Sotera Health had a return on equity of 40.12% and a net margin of 13.44%. The firm's quarterly revenue was up 9.2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.20 earnings per share. Sotera Health has set its FY 2026 guidance at 0.950-1.010 EPS. Sell-side analysts predict that Sotera Health will post 0.87 earnings per share for the current fiscal year.

Sotera Health Company Profile

Sotera Health Company NASDAQ: SHC is a healthcare services company focused on sterilization, laboratory testing and infection prevention. Its services support manufacturers and providers across the medical device, pharmaceutical, tissue, food safety and other healthcare-related industries.

The company operates through three primary businesses. Sterigenics provides outsourced sterilization services, including ethylene oxide, gamma irradiation and electron-beam processing. Nelson Labs offers laboratory testing, analytical services and consulting for medical devices, pharmaceuticals and other healthcare products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.